Mark Alles, Executive Chairman of TORL BioTherapeutics, LLC (TORL) and former Chairman and CEO of Celgene Corporation has been appointed TORL’s Chairman and CEO. Mark brings more than 35 years of global biopharmaceutical experience, and will lead TORL as it advances its expanding clinical-stage antibody programs in oncology and builds additional programs through the high-value discovery pipeline established and led by TORL Scientific Founder Dennis Slamon, M.D., Ph.D.